Drug Trial Radar · NCT07836270
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Oct 31, 2026
Primary completion
Jun 8, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
Conditions
- Adolescents With Obesity
- Adolescents With Overweight & Weight-related Comorbidities
Interventions
Ecnoglutide InjectionDrug
Subcutaneous injection
placebo with matching volumeDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in Body Mass Index (BMI)Time frame: Baseline, week 40
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.